Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease: a systematic review.

J. Gisbert,F. Gomollón,J. Mate,J. Pajares

Published 2002 in Digestive Diseases and Sciences

ABSTRACT

No abstract is available for this paper.

PUBLICATION RECORD

Publication year
2002
Venue
Digestive Diseases and Sciences
Publication date
Unknown publication date
Fields of study
Medicine
Identifiers
PMID 11911332
External record
Open on Semantic Scholar
Source metadata
Semantic Scholar, PubMed

CITATION MAP

EXTRACTION MAP

CLAIMS

No claims are published for this paper.

CONCEPTS

No concepts are published for this paper.

REFERENCES

Placebo-controlled trial of oral 5-ASA in relapse prevention of Crohn's disease
2005cited by this paper
Topical 5-aminosalicylic acid versus prednisolone in ulcerative proctosigmoiditis
2005cited by this paper
Oral 5-aminosalicylic acid for inducing remission in ulcerative colitis.
2000cited by this paper
Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI.
2000cited by this paper
Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease.
2000cited by this paper
Oral 5-aminosalicylic acid for maintaining remission in ulcerative colitis.
2000cited by this paper
[Budesonide foam as a new therapeutic principle in distal ulcerative colitis in comparison with mesalazine enema. An open, controlled, randomized and prospective multicenter pilot study].
2000cited by this paper
A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis
2000cited by this paper
Mesalamine and relapse prevention in Crohn's disease.
2000cited by this paper
Long-term use of mesalamine (Rowasa) suppositories in remission maintenance of ulcerative proctitis
2000cited by this paper
Medical therapy to reduce postoperative Crohn's disease recurrence
2000cited by this paper
Is maintenance therapy always necessary for patients with ulcerative colitis in remission?
1999cited by this paper
Oral mesalazine for the treatment of Crohn's disease: clinical efficacy with respect to pharmacokinetic properties.
1999cited by this paper
Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis
1999cited by this paper
A new mesalazine gel enema in the treatment of left‐sided ulcerative colitis: a randomized controlled multicentre trial
1999cited by this paper
Oral delayed-release mesalazine: a review of its use in ulcerative colitis and Crohn's disease.
1999cited by this paper
Mesalamine in the treatment of mild to moderate active Crohn's ileitis: results of a randomized, multicenter trial.
1999cited by this paper
Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial.
1999cited by this paper
A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease
1999cited by this paper
Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis
1998cited by this paper
Dose-ranging study of mesalamine (PENTASA) enemas in the treatment of acute ulcerative proctosigmoiditis: results of a multicentered placebo-controlled trial. The U.S. PENTASA Enema Study Group.
1998cited by this paper
Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months
1998cited by this paper
Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group.
1998cited by this paper
What dose of 5-aminosalicylic acid (mesalazine) in ulcerative colitis?
1998cited by this paper
A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.
1998cited by this paper
Double‐blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis
1997cited by this paper
Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables.
1997cited by this paper
A trial of zileuton versus mesalazine or placebo in the maintenance of remission of ulcerative colitis. The European Zileuton Study Group For Ulcerative Colitis.
1997cited by this paper
Controlled trial of oral 5‐aminosalicylic acid for the prevention of early relapse in Crohn's disease
1997cited by this paper
A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group.
1997cited by this paper
Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives.
1996cited by this paper
An Oral Preparation of Mesalamine as Long-Term Maintenance Therapy for Ulcerative Colitis
1996cited by this paper
A comparison of mesalamine suspension enema and oral sulfasalazine for treatment of active distal ulcerative colitis in adults.
1996cited by this paper
A randomised trial comparing mesalazine and prednisolone foam enemas in patients with acute distal ulcerative colitis.
1996cited by this paper
Placebo‐controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease
1996cited by this paper
Beclomethasone dipropionate (3 mg) versus 5-aminosalicylic acid (2 g) versus the combination of both (3 mg/2 g) as retention enemas in active ulcerative proctitis.
1996cited by this paper
Comparison of budesonide and 5‐aminosalicylic acid enemas in active distal ulcerative colitis
1995cited by this paper
Coated oral 5-aminosalicylic acid (Claversal) is equivalent to sulfasalazine for remission maintenance in ulcerative colitis. A double-blind study.
1995cited by this paper
Quality-of-life results of double-blind, placebo-controlled trial of mesalamine in patients with Crohn's disease
1995cited by this paper
Mesalazine suppositories versus hydrocortisone foam in patients with distal ulcerative colitis. A comparison of the efficacy and practicality of two topical treatment regimens.
1995cited by this paper
Mesalazine (Mesasal/Claversal) 1.5 g b.d. vs. placebo in the maintenance of remission of patients with Crohn's disease
1995cited by this paper
Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease.
1995cited by this paper
Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group.
1995cited by this paper
Rectal aminosalicylate therapy for distal ulcerative colitis: a meta‐analysis
1995cited by this paper
Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group.
1995cited by this paper
Comparison between high dose 5-aminosalicylic acid and 6-methylprednisolone in active Crohn's ileocolitis. A multicenter randomized double-blind study. German 5-ASA Study Group.
1995cited by this paper
A controlled double blind multicenter study of the effectiveness of 5-aminosalicylic acid in patients with Crohn's disease in remission.
1995cited by this paper
5-Aminosalicylic acid enemas to maintain remission in left-sided ulcerative colitis: a meta- and economic analysis.
1995cited by this paper
Double-blind comparative study of sulfasalazine and controlled-release mesalazine tablets in the treatment of active ulcerative colitis.
1995cited by this paper
Olsalazine versus sulphasalazine for relapse prevention in ulcerative colitis: a multicenter study.
1995cited by this paper
Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Dutch Pentasa Study Group.
1995cited by this paper
Low Pentasa dosage versus hydrocortisone in the topical treatment of active ulcerative colitis: a randomized, double-blind study.
1995cited by this paper
Optimum dose of olsalazine for maintaining remission in ulcerative colitis.
1994cited by this paper
Oral mesalazine (5‐aminosalicylic acid; Asacol) for the prevention of post‐operative recurrence of Crohn's disease
1994cited by this paper
Mesalamine capsules enhance the quality of life for patients with ulcerative colitis
1994cited by this paper
Sulfasalazine and mesalazine for the maintenance therapy of Crohn's disease: a meta-analysis.
1994cited by this paper
5-ASA enema versus oral sulphasalazine in maintaining remission in ulcerative colitis.
1994cited by this paper
A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis.
1994cited by this paper
Second trial of mesalamine therapy in the treatment of active Crohn's disease.
1994cited by this paper
Effectiveness of 5-aminosalicylic acid for maintaining remission in patients with Crohn's disease: a meta-analysis.
1994cited by this paper
Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group.
1993cited by this paper
Olsalazine in maintenance of clinical remission in patients with ulcerative colitis
1993cited by this paper
Comparison of bismuth citrate and 5-aminosalicylic acid enemas in distal ulcerative colitis: a controlled trial.
1993cited by this paper
Sulfasalazine Revisited
1993cited by this paper
Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID)
1993cited by this paper
Long-term management of Crohn's disease with mesalamine capsules (Pentasa). Pentasa Crohn's Disease Compassionate Use Study Group.
1993cited by this paper
Better quality of therapy with 5-ASA colonic foam in active ulcerative colitis
1993cited by this paper
Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group.
1993cited by this paper
Relapse-preventing effect and safety of sulfasalazine and olsalazine in patients with ulcerative colitis in remission: a prospective, double-blind, randomized multicenter study. The Ulcerative Colitis Multicenter Study Group.
1992cited by this paper
Prophylactic effects of olsalazine v sulphasalazine during 12 months maintenance treatment of ulcerative colitis. The Danish Olsalazine Study Group.
1992cited by this paper
Spread and distribution of 5-ASA colonic foam and 5-ASA enema in patients with ulcerative colitis
1992cited by this paper
Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis.
1992cited by this paper
[Efficacy of a daily application of mesalazine (Pentasa) suppository with progressive release, in the treatment of ulcerative proctitis. A double-blind versus placebo randomized trial].
1992cited by this paper
Short report: comparison of two doses of balsalazide in maintaining ulcerative colitis in remission over 12 months
1992cited by this paper
Improved maintenance of remission in ulcerative colitis by balsalazide 4 g/day compared with 2 g/day
1992cited by this paper
Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease. The Italian IBD Study Group.
1992cited by this paper
Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study.
1991cited by this paper
Optimum dosage of 5-aminosalicylic acid as rectal enemas in patients with active ulcerative colitis.
1991cited by this paper
Topical treatment with 5-aminosalicylic in distal ulcerative colitis by using a new suppository preparation
1990cited by this paper
Mesalazine (5-aminosalicylic acid) suppositories in the treatment of ulcerative proctitis or distal proctosigmoiditis. A randomized controlled trial.
1990cited by this paper
Coated oral 5‐aminosalicylic acid versus placebo in maintaining remission of inactive Crohn's disease
1990cited by this paper
5-Aminosalicylic acid suppositories in the maintenance of remission in idiopathic proctitis or proctosigmoiditis: a double-blind placebo-controlled clinical trial.
1990cited by this paper
Double-blind placebo-controlled study of olsalazine in the treatment of ulcerative colitis.
1990cited by this paper
Olsalazine or sulphasalazine in first attacks of ulcerative colitis? A double blind study.
1989cited by this paper
Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.
1989cited by this paper
Olsalazine versus placebo in the treatment of mild to moderate ulcerative colitis: a randomised double blind trial.
1989cited by this paper
Comparative efficacy of coated, oral 5‐aminosalicylic acid (Claversal * ) and sulphasalazine for maintaining remission of ulcerative colitis
1989cited by this paper
Double-blind comparison of olsalazine and sulphasalazine in active ulcerative colitis.
1988cited by this paper
Balsalazide in the maintenance treatment of patients with ulcerative colitis, a double‐blind comparison with sulphasalazine
1988cited by this paper
Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis.
1988cited by this paper
Double-blind comparison of slow-release 5-aminosalicylate and sulfasalazine in remission maintenance in ulcerative colitis.
1988cited by this paper
Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse.
1988cited by this paper
5-Aminosalicylic acid enemas: effective agent in maintaining remission in left-sided ulcerative colitis.
1988cited by this paper
Comparison of 5-aminosalicylic acid (3 g) and prednisolone phosphate sodium enemas (30 mg) in the treatment of distal ulcerative colitis. A prospective, randomized, double-blind trial.
1988cited by this paper
5-Aminosalicylic acid as enemas or suppositories in distal ulcerative colitis?
1988cited by this paper
Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis.
1988cited by this paper
Prospective, randomized, double-blind comparison of benzalazine and sulfasalazine in the treatment of active ulcerative colitis.
1988cited by this paper
5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis.
1987cited by this paper
Double-blind, placebo-controlled evaluation of 5-ASA suppositories in active distal proctitis and measurement of extent of spread using99mTc-labeled 5-ASA suppositories
1987cited by this paper
Olsalazine sodium in the treatment of ulcerative colitis among patients intolerant of sulfasalazine. A prospective, randomized, placebo-controlled, double-blind, dose-ranging clinical trial.
1987cited by this paper

CITED BY

NDP52 and its emerging role in pathogenesis
2025cites this paper
Advances in Colon-Targeted Drug Delivery Systems: Innovative Strategies for Treating Colonic Disorders and Prospects for the Future.
2024cites this paper
Common Mistakes in Managing Patients with Inflammatory Bowel Disease
2024cites this paper
Chitosan functionalized Mn3O4 nanoparticles counteracts ulcerative colitis in mice through modulation of cellular redox state
2023cites this paper
Therapeutic Effect of HDAC5 Binding and Cell Penetrating Peptide for the Treatment of Inflammatory Bowel Disease
2023cites this paper
Normal and Reverse Flow Injection Analysis Methods for Estimation of Mesalazine in Pharmaceutical Dosage Forms
2023cites this paper
N-Acetylglucosamine and its dimer ameliorate inflammation in murine colitis by strengthening the gut barrier function.
2023cites this paper
GADECCU 2022 Guideline for the treatment of Ulcerative Colitis. Adaptation and updating of the GETECCU 2020 Guideline.
2023cites this paper
SECOND BRAZILIAN CONSENSUS ON THE MANAGEMENT OF ULCERATIVE COLITIS IN ADULTS: A CONSENSUS OF THE BRAZILIAN ORGANIZATION FOR CROHN'S DISEASE AND COLITIS (GEDIIB).
2023cites this paper
Systematic review and meta-analysis: association between obesity/overweight and surgical complications in IBD
2022cites this paper
Effect of mesalazine combined with probiotics on inflammation and immune function of patients with inflammatory bowel disease.
2022cites this paper
Ameliorative effect of buckwheat polysaccharides on colitis via regulation of the gut microbiota.
2022cites this paper
In silico analysis of Typha domingensis Pers. phytocompounds against wound healing biomarkers and ascertaining through in vitro cell migration assay
2022cites this paper
From Static to Dynamic: A Review on the Role of Mucus Heterogeneity in Particle and Microbial Transport.
2022cites this paper
Apprehending Ulcerative Colitis Management With Springing Up Therapeutic Approaches: Can Nanotechnology Play a Nascent Role?
2021cites this paper
Nanotechnology for inflammatory bowel disease management: Detection, imaging and treatment
2021cites this paper
Description of the inflammatory bowel disease natural history in Tehran province, Iran: Mixed panel approaches
2021cites this paper
The Communication Between Intestinal Microbiota and Ulcerative Colitis: An Exploration of Pathogenesis, Animal Models, and Potential Therapeutic Strategies
2021cites this paper
Association between vedolizumab and postoperative complications in IBD: a systematic review and meta-analysis
2021cites this paper
Characteristics, Properties and Analytical/Bioanalytical Methods of 5-Aminosalicylic Acid: A Review
2020cites this paper
GETECCU 2020 guidelines for the treatment of ulcerative colitis. Developed using the GRADE approach.
2020cites this paper
Oral Supplementation of Tocotrienol-Rich Fraction Alleviates Severity of Ulcerative Colitis in Mice.
2019cites this paper
Crohn's disease.
2019cites this paper
IBD in the Elderly: Management Challenges and Therapeutic Considerations
2019cites this paper
Korean Traditional Medicine (Jakyakgamcho-tang) Ameliorates Colitis by Regulating Gut Microbiota
2019cites this paper
Pluronic lecithin organogel of 5-aminosalicylic acid for wound healing
2018cites this paper
The clinical effects of probiotics for inflammatory bowel disease
2018cites this paper
Intestinal barrier dysfunction orchestrates the onset of inflammatory host–microbiome cross-talk in a human gut inflammation-on-a-chip
2018cites this paper
Intestinal Organoids Containing PLGA Nanoparticles for the Treatment of Inflammatory Bowel Diseases
2018cites this paper
Crohn Disease: Epidemiology, Diagnosis, and Management
2017cites this paper
Intestinal organoids containing poly(lactic-co-glycolic acid) nanoparticles for the treatment of inflammatory bowel diseases.
2017cites this paper
Применение ведолизумаба при воспалительных заболеваниях кишечника
2017cites this paper
Effect of a probiotic beverage consumption (Enterococcus faecium CRL 183 and Bifidobacterium longum ATCC 15707) in rats with chemically induced colitis
2017cites this paper
Therapeutic requirements in active ulcerative proctitis: A single-centre study.
2017cites this paper
Usefulness of sulfasalazine for patients with refractory-ulcerative colits
2016cites this paper
Physician Perspectives on Unresolved Issues in the Management of Ulcerative Colitis: The UC Horizons Project
2016cites this paper
Development of spectrophotometric method for determination of mesalazine in pharmaceutical preparation
2016cites this paper
Effects of Mesalamine Treatment on Gut Barrier Integrity After Burn Injury
2016cites this paper
Gastroenterología y Hepatología
2016cites this paper
Mesalazine Modified-Release Tablet in the Treatment of Ulcerative Colitis in the Active Phase: A Chinese, Multicenter, Single-Blind, Randomized Controlled Study
2016cites this paper
Short-term effect and adverse events of adalimumab versus placebo in inducing remission for moderate-to-severe ulcerative colitis: a meta-analysis.
2015cites this paper
Effect of Chondroitin Sulphate on Pro-Inflammatory Mediators and Disease Activity in Patients with Inflammatory Bowel Disease
2015cites this paper
Role of heat shock proteins in maintenance of the gut barrier following burn injury
2015cites this paper
In vitro biorelevant models for evaluating modified release mesalamine products to forecast the effect of formulation and meal intake on drug release.
2015cites this paper
A randomized trial comparing 4.8 vs. 2.4 g/day of oral mesalazine for maintenance of remission in ulcerative colitis.
2015cites this paper
Don’t Forget the Doctor: Gastroenterologists’ Preferences on the Development of mHealth Tools for Inflammatory Bowel Disease
2015cites this paper
Evaluation of Intestinal Microbial Diversity and a New Antibiotic Regimen in Crohn's Disease Patients
2015cites this paper
PRISMA—Efficacy and Safety of Vedolizumab for Inflammatory Bowel Diseases
2014cites this paper
Colon-specific prodrugs of 4-aminosalicylic acid for inflammatory bowel disease.
2014cites this paper
Efficacy of topical versus oral 5-aminosalicylate for treatment of 2,4,6-trinitrobenzene sulfonic acid-induced ulcerative colitis in rats
2014cites this paper
The Journal of IHP 3 Nutritional , Nutraceutical , and Herbal Supplements in the Treatment of Inflammatory Bowel Disease
2014cites this paper
Efficacy of topical versus oral 5-aminosalicylate for treatment of 2,4,6-trinitrobenzene sulfonic acid-induced ulcerative colitis in rats
2014cites this paper
Safety of 5-Aminosalicylic Acid Derivatives in Patients with Sensitivity to Acetylsalicylic Acid and Nonsteroidal Anti-inflammatory Drugs.
2014cites this paper
Guía clínica GETECCU del tratamiento de la colitis ulcerosa elaborada con la metodología GRADE
2013cites this paper
[Therapeutic guidelines on ulcerative colitis: a GRADE methodology based effort of GETECCU].
2013cites this paper
Therapeutic guidelines on ulcerative colitis: a GRADE methodology based effort of GETECCU.
2013cites this paper
Mesalazine suppositories and their clinical application
2013cites this paper
Chapter-6 Determination of Mesalamine Related Impurities in Mesalamine Delayed Release Tablets
2013cites this paper
The GETECCU clinical guideline for the treatment of ulcerative colitis:: A guideline created using GRADE methodology
2013cites this paper
Chapter-5 Aniline / Genotoxic Impurity Determination in Mesalamine Delayed Release Tablets by UPLC Overview
2013cites this paper
The emerging role of vedolizumab in the treatment of ulcerative colitis
2012cites this paper
Oxidative stress as a mechanism underlying sulfasalazine-induced toxicity
2011cites this paper
Common misconceptions about 5-aminosalicylates and thiopurines in inflammatory bowel disease.
2011cites this paper
Crohn's disease.
2011cites this paper
Design and development of a stimuli-responsive oral tablet system for the treatment of ulcerative colitis
2011cites this paper
Layered lipid microcapsules for mesalazine delayed-release in children.
2011cites this paper
Usefulness of salicylate and thiopurine coprescription in steroid-dependent ulcerative colitis and withdrawal strategies
2010cites this paper
Meta‐analysis: the effect and adverse events of Lactobacilli versus placebo in maintenance therapy for Crohn disease
2009cites this paper
Development and in vitro evaluation of mesalamine delayed release pellets and tableted reservoir-type pellets
2009cites this paper
Treatment of inflammatory bowel disease: a review of medical therapy.
2008cites this paper
Drug Safety in Crohn’s Disease Therapy
2008cites this paper
Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial
2008cites this paper
Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin.
2008cites this paper
Effect of 5-aminosalicylates on renal function in patients with inflammatory bowel disease: 4-year follow-up study.
2008cites this paper
Acute Tubular Injury Associated with Mesalazine Therapy in an Adolescent Girl with Inflammatory Bowel Disease
2007cites this paper
5‐Aminosalicylates and renal function in inflammatory bowel disease: A systematic review
2007cites this paper
Clinical trial: randomized‐controlled clinical study comparing the efficacy and safety of a low‐volume vs. a high‐volume mesalazine foam in active distal ulcerative colitis
2007cites this paper
Transport of Nicotinate and Structurally Related Compounds by Human SMCT1 (SLC5A8) and Its Relevance to Drug Transport in the Mammalian Intestinal Tract
2007cites this paper
Combined oral and topical mesalazine treatment for extensive ulcerative colitis
2006cites this paper
Double-Blind Pilot Study of Mesalamine vs. Placebo for Treatment of Chronic Diarrhea and Nonspecific Colitis in Immunocompetent HIV Patients
2006cites this paper
The Case for Using 5‐Aminosalicyclates in Crohn's Disease: Pro
2005cites this paper
Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin.
2005cites this paper
Expression, purification, characterization and structure of Pseudomonas aeruginosa arylamine N-acetyltransferase.
2005cites this paper
Drug Safety in the Treatment of Crohn’s Disease
2005cites this paper
Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1‐year follow‐up study
2005cites this paper
Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease.
2005cites this paper
Medical and surgical management of chronic ulcerative colitis.
2005cites this paper
Colonic targeting of aminosalicylates for the treatment of ulcerative colitis.
2005cites this paper
Drug Bioactivation Covalent Binding to Target Proteins and Toxicity Relevance
2005cites this paper
A Randomized, Double‐blind Trial of Lactobacillus GG Versus Placebo in Addition to Standard Maintenance Therapy for Children with Crohn's Disease
2005cites this paper
Review article: the long-term management of ulcerative colitis.
2004cites this paper
Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County.
2004cites this paper
Review article: aminosalicylates in inflammatory bowel disease.
2004cites this paper
Aminosalicylates in inflammatory bowel disease
2004cites this paper
The long‐term management of ulcerative colitis
2004cites this paper
Mucosal healing in children with Crohn's disease: appropriate therapeutic goal or medical overkill?
2004cites this paper
Mesalamine derivatives in the treatment of Crohn's disease.
2004cites this paper
Tolerance of 4-aminosalicylic acid enemas in patients with inflammatory bowel disease and 5-aminosalicylic-induced acute pancreatitis.
2004influential citation
No dose-dependent tubulotoxicity of 5-aminosalicylic acid: a prospective study in patients with inflammatory bowel diseases
2003cites this paper
Combined scintigraphic and pharmacokinetic investigation of enteric‐coated mesalazine micropellets in healthy subjects
2003cites this paper